← SynDRA
DOLUTEGRAVIR
SynDRA canonical compound SYN0024125 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | CYP3A4 | CYP3A5 | CYP3A7 | POU2F2 | SLC22A2 | UGT1A1 |
|---|
| Mechanism of action | HIV integrase inhibitor |
|---|
| Indication | human immunodeficiency virus (HIV-1) |
|---|
| Disease area | infectious disease |
|---|
All known targets
- CYP3A4
- CYP3A5
- CYP3A7
- HIV IN
- POU2F2
- SIGMAR1
- SLC22A2
- Sigmar1
- Slc18a3
- TMEM97
- Tmem97
- UGT1A1
Mechanisms of action (all sources)
- HIV integrase inhibitor
- Modulator
- pol INHIBITOR
Drug classes
- HIV Integrase Inhibitors
- Anti-HIV Agents
- Anti-Infective Agents
- Anti-Retroviral Agents
- Antiviral Agents
- Enzyme Inhibitors
- Integrase Inhibitors
- Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor
- Organic Cation Transporter 2 Inhibitors
- Multidrug and Toxin Extrusion Transporter 1 Inhibitors
ATC classes
- J05A · DIRECT ACTING ANTIVIRALS
Cross-references
Synonyms
- dolutegravir sodium
- tivicay
- GSK 1349572
- S-349572
- GSK-1349572
- GSK1349572
- GSK1349572A
- Tivicay
- S/GSK1349572
- Dolutegravir (GSK1349572)
- UNII-DKO1W9H7M1
- (4r,12as)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2h-Pyrido[1',2':4,5]pyrazino[2,1-B][1,3]oxazine-9-Carboxamide
- CHEBI:76010
- DKO1W9H7M1
- Tivicay (TN)
- (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
- Dolutegravir Sodium (
- Dolutegravir DTG
- Dolutegravir [USAN]
- Dolutegravir (USAN)
- 1051375-16-6 (free)
- (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0^{3,8}]tetradeca-10,13-diene-13-carboxamide
- (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide
- S-GSK1349572
- Dolutegravir [USAN:INN]
- Soltegravir
- HSDB 8152
- 3s3m
- 3s3n
- 3s3o
- (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[[?]:[?]]pyrazino[[?]][1,3]oxazine-9-carboxamide
- DOLUTEGRAVIR [MI]
- DOLUTEGRAVIR [INN]
- DOLUTEGRAVIR [VANDF]
- SCHEMBL82071
- MLS006011137
- DOLUTEGRAVIR [WHO-DD]
- GTPL7365
Reported adverse events
- Arthralgia
- Headache
- Hypersensitivity
- Abdominal pain
- Abnormal dreams
- Depression
- Dizziness
- Fatigue
- Hepatitis
- Insomnia
- Nausea
- Pruritus
Look up DOLUTEGRAVIR in the interactive SynDRA portal →